<p>RNS 编号：3490D Trium Capital LLP2025 年 10 月 14 日</p>
<p>表格 8.3</p>
<p>爱尔兰收购委员会</p>
<p>根据 1997 年爱尔兰收购委员会法第 8.3 条的规定，关于相关证券的开盘头寸披露/交易披露</p>
<p>规则，2022 年由持有 1% 或以上相关证券的人员披露</p>
<p>1. 关键信息</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) 披露者的全名</td>
<td>Trium Capital LLP</td>
</tr>
<tr>
<td>(b) 披露的利益和空头头寸的所有者或控制者（如果与 1(a) 不同）<br/>提名或公司名称不足以说明。对于信托，必须列出受托人、设立人和受益人。</td>
<td></td>
</tr>
<tr>
<td>(c) 与本表相关的要约方/被要约方的名称<br/>每个要约方/被要约方使用单独的表格</td>
<td>MURAL ONCOLOGY PLC</td>
</tr>
<tr>
<td>(d) 如果是与要约方/被要约方相关的豁免基金经理，请说明并指定要约方/被要约方的身份（注 1）</td>
<td></td>
</tr>
<tr>
<td>(e) 持有头寸/进行交易的日期<br/>对于开盘头寸披露，请说明披露前最新的可行日期</td>
<td>2025 年 10 月 13 日</td>
</tr>
<tr>
<td>(f) 除上述 1(c) 中的公司外，披露者是否还在对任何其他要约方进行披露？<br/>如果是现金要约或可能的现金要约，请说明 “N/A”</td>
<td>N/A<br/>:</td>
</tr>
</tbody>
</table>
<p>2. 利益和空头头寸</p>
<p>如果需要披露的要约方或被要约方在 1(c) 中列出的相关证券的多个类别中存在利益和空头头寸，请为每个额外类别复制表格 2。</p>
<p>与披露相关的要约方或被要约方的相关证券的利益和空头头寸（如有）</p>
<p>（注 2）</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别 <br/>（注 3）</td>
<td>USD 0.01</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>利益</td>
<td>空头头寸</td>
<td></td>
<td></td>
</tr>
<tr>
<td>数量</td>
<td>%</td>
<td>数量</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>(1) 拥有和/或控制的相关证券</td>
<td>1,849,026</td>
<td>10.71</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) 现金结算衍生品</td>
<td>54,256</td>
<td>0.31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) 股票结算衍生品（包括期权）和购买/出售协议</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>总计</td>
<td>1,903,082</td>
<td>11.02</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>所有利益和所有空头头寸应予以披露。</p>
<p>包括认购新证券的权利和任何未平仓的股票结算衍生品头寸（包括交易期权）或购买或出售相关证券的协议的详细信息，应在补充表格 8 中提供。</p>
<p>3. 披露者的交易（如有）（注 4）</p>
<p>如果在 1(c) 中列出的要约方或被要约方的多个类别的相关证券中有交易，请为每个额外类别复制表格 3(a)、(b)、(c) 或 (d)（视情况而定）。</p>
<p>所有价格和其他货币金额的货币应予以说明。</p>
<p>(a) 购买和销售</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关<br/>证券类别</td>
<td>USD 0.01</td>
</tr>
<tr>
<td>购买/销售</td>
<td>购买</td>
</tr>
<tr>
<td>证券数量</td>
<td>200</td>
</tr>
<tr>
<td>每单位价格<br/>（注 5）</td>
<td>USD 2.07</td>
</tr>
</tbody>
</table>
<p>(b) 现金结算衍生品交易</p>
<p>(c) 股票结算衍生品交易（包括期权）</p>
<p>(i) 写入、出售、购买或变更</p>
<ul>
<li>相关证券类别</li>
<li>产品描述，例如看涨期权</li>
<li>写入、购买、出售、变更等</li>
<li>与期权相关的证券数量（注 6）</li>
<li>每单位行使价格</li>
<li>类型，例如美式、欧式等</li>
<li>到期日</li>
<li>每单位支付/收到的期权金额</li>
</ul>
<p>(ii) 行使</p>
<ul>
<li>相关证券类别</li>
<li>产品描述，例如看涨期权</li>
<li>行使/已行使</li>
<li>证券数量</li>
<li>每单位行使价格（注 5）</li>
</ul>
<p>(d) 其他交易（包括新证券的交易）（注 3）</p>
<ul>
<li>相关证券类别</li>
<li>交易性质，例如认购、转换、行使</li>
<li>详细信息</li>
<li>每单位价格（如适用）（注 5）</li>
</ul>
<p>4. 其他信息</p>
<p>(a) 赔偿和其他交易安排</p>
<ul>
<li>任何赔偿或期权安排的详细信息，或与相关证券相关的任何协议或理解，无论是正式还是非正式，可能诱使披露者与要约方或与要约方协同行动的任何人进行交易或避免交易。不可撤销的承诺和意向书不应包括。如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
<p>(b) 与期权或衍生品相关的协议、安排或理解</p>
<ul>
<li>披露者与任何其他人之间关于本表中提到的任何期权下的相关证券的投票权或与任何衍生品相关的相关证券的投票权或未来收购或处置的任何协议、安排或理解的完整详细信息。如果没有，应予以说明。</li>
<li>无</li>
</ul>
<p>(c) 附件</p>
<ul>
<li>是否附有补充表格 8？</li>
<li>否</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期</td>
<td>2025 年 10 月 14 日</td>
</tr>
<tr>
<td>联系人姓名</td>
<td>Andrew Crick</td>
</tr>
<tr>
<td>电话号码</td>
<td>+44 (0) 20 7073 9269</td>
</tr>
</tbody>
</table>
<p>根据规则 8.3 的规定，公共披露必须向监管信息服务进行。</p>
<p>此信息由 RNS 提供，伦敦证券交易所的新闻服务。RNS 已获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
<p>RNS 可能会使用您的 IP 地址以确认遵守条款和条件，分析您与本通信中包含的信息的互动方式，并在我们的商业服务中以匿名方式与他人共享此分析。如需了解有关 RNS 和伦敦证券交易所如何使用您提供的个人数据的更多信息，请参见我们的隐私政策。结束 ITPBSBDGUDBDGUS</p>

MURA

<p>Trium Capital LLP 根据爱尔兰收购委员会法第 8.3 条披露了其在 Mural Oncology PLC 的持仓。截至 2025 年 10 月 13 日，Trium 持有 1,849,026 股相关证券（10.71%）和现金结算衍生品 54,256 股（0.31%），总计 1,903,082 股（11.02%）。该披露包括以每股 2.07 美元购买的 200 股证券。没有报告其他协议或安排。该披露由 Andrew Crick 于 2025 年 10 月 14 日发布，并提供了联系方式以便进一步咨询</p>

<p>RNS Number : 3490D Trium Capital LLP 14 October 2025</p>
<div class="lb-trans"><p>RNS 编号：3490D Trium Capital LLP2025 年 10 月 14 日</p>
</div><p>FORM 8.3</p>
<div class="lb-trans"><p>表格 8.3</p>
</div><p>IRISH TAKEOVER PANEL</p>
<div class="lb-trans"><p>爱尔兰收购委员会</p>
</div><p>OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER</p>
<div class="lb-trans"><p>根据 1997 年爱尔兰收购委员会法第 8.3 条的规定，关于相关证券的开盘头寸披露/交易披露</p>
</div><p>RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE</p>
<div class="lb-trans"><p>规则，2022 年由持有 1% 或以上相关证券的人员披露</p>
</div><p>1. KEY INFORMATION</p>
<div class="lb-trans"><p>1. 关键信息</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Full name of discloser</td>
<td>Trium Capital LLP</td>
</tr>
<tr>
<td>(b) Owner or controller of interests and short positions disclosed, if different from 1(a)<br/>The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.</td>
<td></td>
</tr>
<tr>
<td>(c) Name of offeror/offeree in relation to whose relevant securities this form relates<br/>Use a separate form for each offeror/offeree</td>
<td>MURAL ONCOLOGY PLC</td>
</tr>
<tr>
<td>(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)</td>
<td></td>
</tr>
<tr>
<td>(e) Date position held/dealing undertaken<br/>For an opening position disclosure, state the latest practicable date prior to the disclosure</td>
<td>13/10/2025</td>
</tr>
<tr>
<td>(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?<br/>If it is a cash offer or possible cash offer, state &#34;N/A&#34;</td>
<td>N/A<br/>:</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) 披露者的全名</td>
<td>Trium Capital LLP</td>
</tr>
<tr>
<td>(b) 披露的利益和空头头寸的所有者或控制者（如果与 1(a) 不同）<br/>提名或公司名称不足以说明。对于信托，必须列出受托人、设立人和受益人。</td>
<td></td>
</tr>
<tr>
<td>(c) 与本表相关的要约方/被要约方的名称<br/>每个要约方/被要约方使用单独的表格</td>
<td>MURAL ONCOLOGY PLC</td>
</tr>
<tr>
<td>(d) 如果是与要约方/被要约方相关的豁免基金经理，请说明并指定要约方/被要约方的身份（注 1）</td>
<td></td>
</tr>
<tr>
<td>(e) 持有头寸/进行交易的日期<br/>对于开盘头寸披露，请说明披露前最新的可行日期</td>
<td>2025 年 10 月 13 日</td>
</tr>
<tr>
<td>(f) 除上述 1(c) 中的公司外，披露者是否还在对任何其他要约方进行披露？<br/>如果是现金要约或可能的现金要约，请说明 “N/A”</td>
<td>N/A<br/>:</td>
</tr>
</tbody>
</table>
</div><p>2. INTERESTS AND SHORT POSITIONS</p>
<div class="lb-trans"><p>2. 利益和空头头寸</p>
</div><p>If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.</p>
<div class="lb-trans"><p>如果需要披露的要约方或被要约方在 1(c) 中列出的相关证券的多个类别中存在利益和空头头寸，请为每个额外类别复制表格 2。</p>
</div><p>Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)</p>
<div class="lb-trans"><p>与披露相关的要约方或被要约方的相关证券的利益和空头头寸（如有）</p>
</div><p>(Note 2)</p>
<div class="lb-trans"><p>（注 2）</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security <br/>(Note 3)</td>
<td>USD 0.01</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Interests</td>
<td>Short positions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number</td>
<td>%</td>
<td>Number</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>(1) Relevant securities owned and/or controlled</td>
<td>1,849,026</td>
<td>10.71</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) Cash-settled derivatives</td>
<td>54,256</td>
<td>0.31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) Stock-settled derivatives (including options) and agreements to purchase/ sell</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>1,903,082</td>
<td>11.02</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别 <br/>（注 3）</td>
<td>USD 0.01</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>利益</td>
<td>空头头寸</td>
<td></td>
<td></td>
</tr>
<tr>
<td>数量</td>
<td>%</td>
<td>数量</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>(1) 拥有和/或控制的相关证券</td>
<td>1,849,026</td>
<td>10.71</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) 现金结算衍生品</td>
<td>54,256</td>
<td>0.31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) 股票结算衍生品（包括期权）和购买/出售协议</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>总计</td>
<td>1,903,082</td>
<td>11.02</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p>All interests and all short positions should be disclosed.</p>
<div class="lb-trans"><p>所有利益和所有空头头寸应予以披露。</p>
</div><p>Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.</p>
<div class="lb-trans"><p>包括认购新证券的权利和任何未平仓的股票结算衍生品头寸（包括交易期权）或购买或出售相关证券的协议的详细信息，应在补充表格 8 中提供。</p>
</div><p>3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)</p>
<div class="lb-trans"><p>3. 披露者的交易（如有）（注 4）</p>
</div><p>Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.</p>
<div class="lb-trans"><p>如果在 1(c) 中列出的要约方或被要约方的多个类别的相关证券中有交易，请为每个额外类别复制表格 3(a)、(b)、(c) 或 (d)（视情况而定）。</p>
</div><p>The currency of all prices and other monetary amounts should be stated.</p>
<div class="lb-trans"><p>所有价格和其他货币金额的货币应予以说明。</p>
</div><p>(a) Purchases and sales</p>
<div class="lb-trans"><p>(a) 购买和销售</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant<br/>security</td>
<td>USD 0.01</td>
</tr>
<tr>
<td>Purchase/sale</td>
<td>Purchase</td>
</tr>
<tr>
<td>Number of<br/>securities</td>
<td>200</td>
</tr>
<tr>
<td>Price per unit<br/>(Note 5)</td>
<td>USD 2.07</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关<br/>证券类别</td>
<td>USD 0.01</td>
</tr>
<tr>
<td>购买/销售</td>
<td>购买</td>
</tr>
<tr>
<td>证券数量</td>
<td>200</td>
</tr>
<tr>
<td>每单位价格<br/>（注 5）</td>
<td>USD 2.07</td>
</tr>
</tbody>
</table>
</div><p>(b) Cash-settled derivative transactions</p>
<div class="lb-trans"><p>(b) 现金结算衍生品交易</p>
</div><p>(c) Stock-settled derivative transactions (including options)</p>
<div class="lb-trans"><p>(c) 股票结算衍生品交易（包括期权）</p>
</div><p>(i) Writing, selling, purchasing or varying</p>
<div class="lb-trans"><p>(i) 写入、出售、购买或变更</p>
</div><ul>
<li>Class of relevant security</li>
<li>Product description e.g. call option</li>
<li>Writing, purchasing, selling, varying etc.</li>
<li>Number of securities to which option relates (Note 6)</li>
<li>Exerciseprice per unit</li>
<li>Type e.g. American, Europeanetc.</li>
<li>Expiry date</li>
<li>Option moneypaid/ received per unit</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>产品描述，例如看涨期权</li>
<li>写入、购买、出售、变更等</li>
<li>与期权相关的证券数量（注 6）</li>
<li>每单位行使价格</li>
<li>类型，例如美式、欧式等</li>
<li>到期日</li>
<li>每单位支付/收到的期权金额</li>
</ul>
</div><p>(ii) Exercise</p>
<div class="lb-trans"><p>(ii) 行使</p>
</div><ul>
<li>Class of relevant security</li>
<li>Product description e.g. call option</li>
<li>Exercising/ exercised against</li>
<li>Number of securities</li>
<li>Exercise price per unit (Note 5)</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>产品描述，例如看涨期权</li>
<li>行使/已行使</li>
<li>证券数量</li>
<li>每单位行使价格（注 5）</li>
</ul>
</div><p>(d) Other dealings (including transactions in respect of new securities) (Note 3)</p>
<div class="lb-trans"><p>(d) 其他交易（包括新证券的交易）（注 3）</p>
</div><ul>
<li>Class of relevant security</li>
<li>Nature of dealing e.g. subscription, conversion, exercise</li>
<li>Details</li>
<li>Price per unit (if applicable) (Note 5)</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>交易性质，例如认购、转换、行使</li>
<li>详细信息</li>
<li>每单位价格（如适用）（注 5）</li>
</ul>
</div><p>4. OTHER INFORMATION</p>
<div class="lb-trans"><p>4. 其他信息</p>
</div><p>(a) Indemnity and other dealing arrangements</p>
<div class="lb-trans"><p>(a) 赔偿和其他交易安排</p>
</div><ul>
<li>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state &#34;none&#34;</li>
<li>NONE</li>
</ul>
<div class="lb-trans"><ul>
<li>任何赔偿或期权安排的详细信息，或与相关证券相关的任何协议或理解，无论是正式还是非正式，可能诱使披露者与要约方或与要约方协同行动的任何人进行交易或避免交易。不可撤销的承诺和意向书不应包括。如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
</div><p>(b) Agreements, arrangements or understandings relating to options or derivatives</p>
<div class="lb-trans"><p>(b) 与期权或衍生品相关的协议、安排或理解</p>
</div><ul>
<li>Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.</li>
<li>NONE</li>
</ul>
<div class="lb-trans"><ul>
<li>披露者与任何其他人之间关于本表中提到的任何期权下的相关证券的投票权或与任何衍生品相关的相关证券的投票权或未来收购或处置的任何协议、安排或理解的完整详细信息。如果没有，应予以说明。</li>
<li>无</li>
</ul>
</div><p>(c) Attachments</p>
<div class="lb-trans"><p>(c) 附件</p>
</div><ul>
<li>Is a Supplemental Form 8 attached?</li>
<li>NO</li>
</ul>
<div class="lb-trans"><ul>
<li>是否附有补充表格 8？</li>
<li>否</li>
</ul>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of disclosure</td>
<td>14/10/2025</td>
</tr>
<tr>
<td>Contact name</td>
<td>Andrew Crick</td>
</tr>
<tr>
<td>Telephone number</td>
<td>+44 (0) 20 7073 9269</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期</td>
<td>2025 年 10 月 14 日</td>
</tr>
<tr>
<td>联系人姓名</td>
<td>Andrew Crick</td>
</tr>
<tr>
<td>电话号码</td>
<td>+44 (0) 20 7073 9269</td>
</tr>
</tbody>
</table>
</div><p>Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.</p>
<div class="lb-trans"><p>根据规则 8.3 的规定，公共披露必须向监管信息服务进行。</p>
</div><p>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</p>
<div class="lb-trans"><p>此信息由 RNS 提供，伦敦证券交易所的新闻服务。RNS 已获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
</div><p>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPBSBDGUDBDGUS</p>
<div class="lb-trans"><p>RNS 可能会使用您的 IP 地址以确认遵守条款和条件，分析您与本通信中包含的信息的互动方式，并在我们的商业服务中以匿名方式与他人共享此分析。如需了解有关 RNS 和伦敦证券交易所如何使用您提供的个人数据的更多信息，请参见我们的隐私政策。结束 ITPBSBDGUDBDGUS</p>
</div>

REG - Trium Capital LLP Mural Oncology PLC - 表格 8.3 - Mural Oncology PLC